Drug Discovery World

NOVEMBER 29, 2022

Using artificial intelligence, researchers at Chalmers University of Technology, Sweden have succeeded in designing synthetic DNA that controls the cells’ protein production. . The technology can contribute to the development and production of vaccines and drugs for severe diseases much faster and at lower cost. .

DNA 52

DNA Development Research Drugs 52

Drug Discovery World

OCTOBER 25, 2022

Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and antibodies to expedite the process of novel drug identification and validation, for example. . Listen here.

Recombinant DNA Technology 52

Recombinant DNA Technology DNA Drugs Protein 52

Drug Discovery World

OCTOBER 25, 2022

Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and antibodies to expedite the process of novel drug identification and validation, for example. .

Recombinant DNA Technology 52

Recombinant DNA Technology DNA Drugs Protein 52

XTalks

APRIL 29, 2021

Sustained viral suppression is achieved through antiretroviral (ARV) therapy, which often consists of a cocktail of two or more ARV drugs that work to inhibit viral replication. HIV drug resistance has ben a problem since ARV drugs were first introduced in the late 1980s.

DNA 98

DNA Drugs RNA Genotype 98

Pharmaceutical Technology

SEPTEMBER 29, 2023

HitGen and the Structural Genomics Consortium entered a collaboration to discover drugs based on a DNA-encoded library (DEL).

DNA 130

DNA Genome Genomics Drugs 130

Drug Discovery World

MAY 24, 2023

Touchlight, a company providing DNA services and manufacturing enzymes, has completed the redevelopment and expansion of its UK manufacturing facility in London, UK. The expanded facility’s manufacturing capacity has tripled and is now capable of producing more than 8kg a year.

DNA 52

DNA Gene Editing Gene Therapy Genetics 52

Drug Discovery World

MAY 11, 2023

The first DNA synthesised using Evonetix’s semiconductor chip technology has been delivered to the Department of Chemical Engineering and Biotechnology at the University of Cambridge. The DNA was delivered to Dr Jenny Molloy, Co-chair of the Engineering Biology Interdisciplinary Research Centre at the University of Cambridge.

DNA 52

DNA Engineer Gene Scientist 52

Drug Discovery World

DECEMBER 4, 2023

A novel DNA vaccine in combination with chemotherapy has demonstrated promising clinical results against a deadly form of ovarian cancer. The investigational compound Elenagen is an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1.

DNA 59

DNA Packaging Packaging Vaccination 59

Scienmag

JANUARY 8, 2021

Dill/NIST In a technique known as DNA origami, researchers fold long strands of DNA over and over again to construct a variety of tiny 3D structures, including miniature biosensors and drug-delivery containers.

DNA 95

DNA Drug Delivery Containment Research 95

pharmaphorum

DECEMBER 3, 2020

Germany’s Merck KGaA has joined with UK-based Artios Pharma in a potential multi-billion dollar deal to investigate novel DNA damage response targets in cancer. The principle of DNA damage response is already being exploited by AstraZeneca and other companies with their poly (ADP-ribose) polymerase (PARP) inhibitor drugs.

DNA 94

DNA Genetics Research Sales 94

Bio Pharma Dive

SEPTEMBER 12, 2022

Scientists at Pretzel believe fixing mutated mitochondrial DNA with a mix of small molecule therapies and gene editing could be key to solving a number of hard-to-treat diseases.

Gene Editing 256

Gene Editing DNA Gene Scientist 256

Pharmaceutical Technology

FEBRUARY 23, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Artificial Intelligence in Pharmaceuticals: In-silico drug discovery. Adimab and Xencor are the other key patent filers of in-silico drug discovery.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

Drug Discovery World

JULY 19, 2022

Non-coding or ‘junk’ DNA could contribute to the development of certain cancers due to how it disrupts the replication of the genome, scientists have discovered. . A team from The Institute of Cancer Research (ICR), London reconstituted the entire process of DNA replication in a test tube in order to understand it more completely. .

DNA 52

DNA Genome Genomics Genetics 52

Bio Pharma Dive

OCTOBER 25, 2022

“Every struggle that I've had has woven a sense of persistence into my DNA,” said Zhang, in a wide-ranging interview about leading a biotech startup as a young CEO.

Genome 265

Genome Genomics DNA Drugs 265

Scienmag

MAY 3, 2021

Detection innovation could enhance drug development and cancer research Credit: Richard Hooley/UCR Small changes in the structure of DNA have been implicated in breast cancer and other diseases, but they’ve been extremely difficult to detect — until now.

DNA 98

DNA Development Drugs Research 98

Bio Pharma Dive

MAY 13, 2021

With $82 million in hand, Flare Therapeutics is looking to create precision cancer drugs by going after a type of protein called transcription factors.

Regulation 234

Regulation DNA Protein Drugs 234

Drug Discovery World

AUGUST 16, 2023

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. Many scientists are now discovering that this junk DNA plays an essential role in our biology and the epigenetic processes that respond to the environment to drive disease.

RNA 52

RNA Genome Genomics DNA 52

pharmaphorum

SEPTEMBER 14, 2021

Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as ‘junk’ – for hidden treasure. Most drug discovery programmes target the roughly 2% of the human genome which encodes for protein.

DNA 52

DNA Immune Response Genome Genomics 52

Bio Pharma Dive

OCTOBER 19, 2020

The trial would be the first test of a systemically administered gene editing treatment that uses the Nobel Prize-winning technology to alter DNA.

Gene Editing 315

Gene Editing DNA Gene Drugs 315

Drug Discovery World

APRIL 19, 2023

Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. Image: Human breast cancer cells stained for DNA (red). New treatments aim to take advantage in cancer cells’ DNA repair mechanisms.

DNA 98

DNA Development Drugs Genome 98

pharmaphorum

JANUARY 6, 2021

Pharma companies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. Encoded within a successful emblem is a company’s DNA – its history, its future.

DNA 116

DNA Branding Vaccination Vaccine 116

BioTech 365

MAY 27, 2021

Whitepaper: Advancing Drug Discovery Through DNA Encoded Library Technology! Whitepaper: Advancing Drug Discovery Through DNA Encoded Library Technology! Available Now! Available Now!

DNA 40

DNA Drugs 40

Scienmag

SEPTEMBER 28, 2020

Brazilian research group shows that valproic acid (VPA), used to treat epilepsy since the 1960s, modulates gene expression in tumor gene models and acts on DNA conformation and the histones in chromatin Results of recent studies involving valproic acid, used for decades as an anti-convulsant drug, show that it can interact with the conformation of (..)

DNA 70

DNA Gene Expression Protein Gene 70

Scienmag

APRIL 10, 2022

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers — ATR inhibitor elimusertib and PARP inhibitor AZD5305 — are safe and clinically beneficial in treating patients with advanced solid tumors. NEW ORLEANS ? Principal investigator Timothy Yap, M.B.B.S.,

DNA 57

DNA Clinical Trials Clinical Trials Trials 57

Pharmaceutical Technology

APRIL 11, 2023

The US Food and Drug Administration (FDA) has granted final approval to India-based Zydus Lifesciences ‘ 500mg azithromycin tablets for the treatment of bacterial infections. Zydus will manufacture the drug at its formulation facility in Moraiya, Ahmedabad, in the Indian state of Gujarat.

FDA Approval 130

FDA Approval Drugs Immune Response Manufacturing 130

Drug Discovery Today

MAY 25, 2023

The Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London.

DNA 45

DNA Manufacturing Genetics Medicine 45

BioTech 365

FEBRUARY 3, 2022

DNA Methyltransferase Inhibitor Drug Pipeline Market Research Report 2022 Featuring Rexahn Pharmaceuticals, SuperGen, & SignalRx Pharmaceuticals – ResearchAndMarkets.com DNA Methyltransferase Inhibitor Drug Pipeline Market Research Report 2022 Featuring Rexahn Pharmaceuticals, SuperGen, & SignalRx Pharmaceuticals – ResearchAndMarkets.com (..)

DNA 40

DNA Marketing Research Drugs 40

Pharmaceutical Technology

MAY 24, 2023

Inovio has received orphan drug designation for INO-3107 from the European Commission (EC) to treat recurrent respiratory papillomatosis (RRP). In July 2020, the US Food and Drug Administration (FDA) also granted orphan drug designation to INO-3107.

Drugs 130

Drugs DNA Medicine Regulation 130

Scienmag

SEPTEMBER 28, 2020

A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial – highlighting the potential of a new class of drugs known as ATR inhibitors.

DNA 51

DNA Clinical Trials Clinical Trials Drugs 51

BioTech 365

MAY 24, 2021

Dorian and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery Dorian and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery CHENGDU, China–(BUSINESS WIRE)–Shanghai Stock Exchange listed company HitGen Inc.

DNA 40

DNA Research Drugs 40

Drug Discovery World

NOVEMBER 23, 2022

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell or gene therapies that require pDNA as a starting material.

DNA 52

DNA Manufacturing Gene Therapy Gene 52

BioTech 365

APRIL 5, 2021

HitGen and BioAge Announce Research Progress in DNA-Encoded Library Based Drug Discovery Research Collaboration HitGen and BioAge Announce Research Progress in DNA-Encoded Library Based Drug Discovery Research Collaboration CHENGDU, China–(BUSINESS WIRE)–Shanghai Stock Exchange listed biotech company HitGen Inc.

DNA 40

DNA Research Drugs 40

BioSpace

DECEMBER 30, 2020

From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.

DNA 136

DNA Drugs Vaccination Vaccine 136

Bio Pharma Dive

NOVEMBER 14, 2022

The RNA drug developer is paying the richly-funded startup $80 million in a wide-ranging alliance that marks its first foray into DNA editing medicines.

Gene Editing 156

Gene Editing RNA DNA Gene 156

BioTech 365

DECEMBER 3, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Merck KGaA pens major cancer drugs biobucks pact with DNA damage biotech Artios Pharma.Merck KGaA pens major cancer drugs biobucks pact with DNA damage biotech Artios Pharma … Continue reading →

DNA 40

DNA Drugs Research 40

Drug Discovery World

MAY 25, 2023

DNA Script: SYNTAX DNA printing platform Using the company’s EDS technology, the SYNTAX platform can synthesise up to 96 highly accurate, ready-to-use DNA oligos with maximum lengths of up to 120nt in less than 24 hours in the laboratory. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos.

Production 52

Production Reagent DNA Drugs 52

pharmaphorum

NOVEMBER 22, 2021

The 2nd annual Mitochondria-Targeted Drug Development Summit returns as the only industry-led meeting focused on overcoming the challenge of treating unmet medical needs caused by mitochondrial dysfunction. The Relationship of Mitochondrial DNA (mtDNA) Mutations/Damage & Mitochondrial Reactive Oxygen Species (ROS) Dysfunction.

Development 98

Development Drugs DNA Gene Therapy 98